CRBN E3 ubiquitin ligase complex CRL4-CRBN | News Search

跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

找到 10,912 条关于 “CRBN E3 ubiquitin ligase complex CRL4-CRBN”

Kangpu Biopharmaceuticals' KPG-818 Demonstrates Favorable Safety Profile in China Bridging Study

The Second Act of Thalidomide: From Teratogen to the Foundation of Targeted Protein Degradation

Kangpu's Novel Molecular Glue Modulator KPG-818 Receives IND Approval in China for Multiple Myeloma Treatment

Kangpu's Novel Cereblon Modulator Shows 50% Response Rate in Heavily Pre-treated Multiple Myeloma Patients

Identification and Characterization of Mitochondrial E3 Ubiquitin Protein Ligase 1 (MUL1) in Disease Regulation

CRBN Gene Mutations Show Variable Impact on Myeloma Drug Response, Enabling Precision Treatment Selection

ADAR1 Gene Identified as Key Driver of Lenalidomide Resistance in Multiple Myeloma

Molecular Glue Degraders of HuR Suppress BRAF-Mutant Colorectal Cancer

Amphista Therapeutics Advances Novel BRD9 Degraders Using Proprietary Targeted Glue Technology

RARα-Targeting PROTAC Delivered by Plant Nanoparticles Shows Potent Activity in Colorectal Cancer

第 1 页，共 550 页